Low-dose HDACi potentiates anti-tumor activity of macrophages in immunotherapy
The success of checkpoint immunotherapy has created optimism that cancer may be curable. However, not all patients respond, resistance is common and many patients relapse owing to immune escape. We demonstrate that HDAC inhibition not only decreases the trafficking of myeloid-derived suppressor cell...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2021-01-01
|
| Series: | OncoImmunology |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/2162402X.2021.1935668 |